Kenvue Inc

Kenvue Inc(KVUE)の株式分析

$18.670

+0.683 (+3.66%)終値時点

Loading chart…
高値
18.770
始値
18.380
出来高加重平均価格
18.61
出来高
26.39M
時価総額
35.27B
安値
18.380
売買代金
490.98M
EV/EBITDA(TTM)
11.44

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

www.kenvue.com

AI分析 of Kenvue Inc (KVUE)

買い

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

アナリスト評価(1)

上値余地 +1.02%
売り
0 買い
0 中立
1 売り
現在: 18.67
安値
17.00
平均
18.86
高値
23.00

UBS

2026-08-11

目標株価

$19

中立

Barclays

2026-07-21

目標株価

$19

Equal Weight

UBS

2026-07-16

目標株価

$20

中立

Citi

2026-04-15

目標株価

$19

中立

Barclays

2026-04-14

目標株価

$18

Equal Weight

バリュエーション指標

Kenvue Inc(KVUE)の現在の予想PERは14.73で、5年平均は17.52です。

予想PER

割安
5年平均 P/E
17.52
現在のP/E
14.73
割高
19.72
割安
15.33

予想EV/EBITDA

割安
5年平均 EV/EBITDA
12.65
現在のEV/EBITDA
11.44
割高
13.80
割安
11.50

予想PSR

適正
5年平均 P/S
2.48
現在のP/S
2.17
割高
2.81
割安
2.15

Alphio AI による KVUE の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%KVUE

$25.34

シナリオ価格

基

基本

基本 · 50%KVUE

$22.26

シナリオ価格

弱

弱気

弱気 · 25%KVUE

$19.40

シナリオ価格

KVUE を保有するクジラ

I

Ingalls & Snyder, LLC

+ を保有KVUE

+10.87%

3か月リターン

M

Millennium Management LLC

+ を保有KVUE

+10.05%

3か月リターン

T

Troy Asset Management Ltd

+ を保有KVUE

+7.07%

3か月リターン

B

Burgundy Asset Management Ltd.

+ を保有KVUE

+6.98%

3か月リターン

T

Trajan Wealth, L.L.C.

+ を保有KVUE

+6.51%

3か月リターン

Y

Yacktman Asset Management LP

+ を保有KVUE

+6.39%

3か月リターン

KVUE のよくある質問 — Alphio AI が回答

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める